However, we have found in the present study that different selective Mediator kinase inhibitors suppress the growth of TNBC tumors, extend the survival of metastatic disease, and potentiate drugs targeting mTOR and AKT, preventing, at least in some cases, the tumor adaptation to therapy. Here, MTOR is linked to metastatic neoplasm.